[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Transatlantic update and personal experience", "description": "United States\n\nCases, + 102,004 = 27,229.862\n\nDearth, +3,589 = 474,423 (0.14% of population)\n\nHospitalizations, 69,283 (14,369, 4,643)\n\nVaccine doses since 14th December, 50, 641,884\n\nFirst dose, 37,056,122\n\nBooster doses, 13,082,172 (4.08%)\n\nUS COVID-19 Cases Caused by Variants\n\nhttps://www.cdc.gov/coronavirus/2019-ncov/transmission/variant-cases.html\n\nUS B.1.1.7 dashboard\n\nhttps://www.helix.com/pages/helix-covid-19-surveillance-dashboard\n\nFlorida\nCalifornia\nGeorgia\nTexas\n\nCDC data\n\nhttps://covid.cdc.gov/covid-data-tracker/#trends_dailytrendscases\n\nPast 7 days\n\nhttps://www.washingtonpost.com/graphics/2020/national/coronavirus-us-cases-deaths/?itid=sf_coronavirus\n\nNew daily reported cases, down 22.1%\n\nNew daily reported deaths, down 5.8%\n\nCoViD related hospitalizations, down 17.8%\n\nTest positivity rate, 5.8%\n \nhttps://covidtracking.com/data\n\nUnited kingdom\n\nUK data\n\nCases, + 13,308 = 4,027,106\n\nDeaths, + 621 = 116,908 (0.18% of population)\n\nVaccinations\n\nFirst dose, 14,556,827\n\nSecond dose, 534,869\n\nhttps://coronavirus.data.gov.uk/details/cases\n\nTracker app data\n\nhttps://covid.joinzoe.com/data#levels-over-time\n\nhttps://twitter.com/DavidDavisMP\n\nOxford University extends COVID-19 vaccine study to children\n\nhttps://www.ovg.ox.ac.uk/news/oxford-university-extends-covid-19-vaccine-study-to-children\n\n 13th February\n\nLondon, Southampton and Bristol\n\nSafety and immune responses in children and young adults\n\nAges, 6 to 17 years\n\nSingle-blind, randomised phase II trial\n\nN =  300 volunteers\n\nVaccine group, n = 240\n\nControl group, n = 60, meningitis vaccine\n\nSafe and gives a sore arm\n\nAndrew Pollard\n\nProfessor of Paediatric Infection and Immunity, and Chief Investigator on the Oxford vaccine trial\n\nWhile most children are relatively unaffected by coronavirus and are unlikely to become unwell with the infection, \n\nit is important to establish the safety and immune response to the vaccine in children and young people as some children may benefit from vaccination. \n\nThese new trials will extend our understanding of control of SARS-CoV2 to younger age groups\n\nStarting trials for younger children this spring\n\nPfizer\n\nModerna\n\nJanssen", "link": "https://www.youtube.com/watch?v=_Y2VaJhjhFc", "date_published": "2021-02-14 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Spain, convincing therapeutic evidence", "description": "Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study (October 2020)\n\nhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456194/\n\nn = 76, Calcifediol treatment\n\n50 patients treated with calcifediol\n\nOne required admission to ICU (2%)\n\nNo deaths\n\n26 untreated patients\n\n13 required admission to ICU (50 %)\n\n2 deaths\n\nCalcifediol treatment and COVID-19-related outcomes\n\n(22nd January)\n\nBarna-COVIDIOL\n\nBarcelona\n\nhttps://papers.ssrn.com/sol3/papers.cfm?abstract_id=3771318\n\n \n\nEffect of calcifediol treatment\n\nIn admitted patients\n\nOn ICU admission\n\nand mortality\n\nN = 930\n\nRandomly assigned\n\nCalcifediol treatment group n = 551\n\nDay one, 532 ug (21,000 iu)\n\nDays, 3, 7, 15, 30, 266 ug (10,640 iu)\n\nNo adverse effects reported\n\nRequired ICU, 30 (5.4%) \n\nDeaths, 36 (6.5%)\n\nDeath RR = 0.36\n\n64% reduced chance of death\n\nControl group n = 379\n\nRequired ICU, 80 (21.1%), p less than 0.0001\n\nDeaths, 57 (15%), p = 0.001\n\n\nAdjusted for\n\nAge\n\nSex\n\nComorbidities\n\nLinearized 25(OH)D levels at baseline\n\nTreated patients\n\nReduced risk to require ICU\n\nRR 0.18\n\nBaseline 25(OH)D levels\n\nInversely correlated with the risk of ICU\n\nPredictors of reduced mortality\n\nHigher baseline 25(OH)D levels\n\nPredictors on increased mortality\n\nAge\n\nObesity\n\nInterpretation\n\nIn patients hospitalized with COVID-19, calcifediol treatment at the time of hospitalization significantly reduced ICU admission and mortality.\n\nEarly calcifediol after admission\n\nPrior to ARDS development, is critical for mortality reduction\n\nInitiation of calcifediol during ICU admission did not modify patient survival", "link": "https://www.youtube.com/watch?v=oYK9-zvJF_k", "date_published": "2021-02-13 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]